Clinical Trials Logo

Filter by:
NCT ID: NCT06311045 Not yet recruiting - Clinical trials for Obstructive Sleep Apnea

Obstructive Sleep Apnea (OSA) and Sex-Specific Responses to N-acetylcysteine (NAC)

Start date: April 2024
Phase: N/A
Study type: Interventional

This is a randomized controlled trial (RCT) of 4 weeks of study supplement N-acetylcysteine (NAC) versus placebo in persons with significant obstructive sleep apnea (OSA) who are receiving positive airway pressure therapy (PAP), the standard of care therapy. The purpose of the study is to determine if NAC is associated with sex-specific changes in overnight oxidative stress, inflammation, as well as endothelial dysfunction in persons with OSA.

NCT ID: NCT06310551 Not yet recruiting - HIV Infections Clinical Trials

First Time in Human Study of Long Acting VH4524184 Formulations

Start date: March 14, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to identify 1 or more doses of parenterally administered VH4524184 that are safe, well tolerated and yield a PK drug exposure profile necessary to deliver a long-acting antiretroviral therapy for the treatment of HIV-1 infection.

NCT ID: NCT06310213 Not yet recruiting - Clinical trials for Hydrocephalus in Infants

Non-Invasive Pressure Monitor for Neonates & Infants at Risk of Developing Hydrocephalus

Start date: April 1, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to test a modified smart soft contact lens in neonates and infants at risk of developing hydrocephalus. The main questions it aims to answer are: - Can the device distinguish between intracranial pressure variations in neonates and infants diagnosed with hydrocephalus and those without - Can the device compare pressure dynamics between pre- and post-operative periods in neonates and infants who undergo surgical treatments Participants will undergo standard of care evaluations for hydrocephalus (anterior fontanelle assessment and head circumference measurement) and wear the device during standard of care evaluation; pre- and post- ventricular reservoir taps, as applicable; and/or pre- and post-operatively, as applicable.

NCT ID: NCT06309602 Not yet recruiting - Clinical trials for Oropharyngeal Dysphagia

Investigation of a Free Water Protocol

Start date: April 15, 2024
Phase: N/A
Study type: Interventional

Hypothesis: Use of a Free Water Protocol (FWP) will improve patient satisfaction scores (Dysphagia Handicap Index), will not increase the risk of aspiration pneumonia/pneumonitis, and will result in improved oral hygiene (as assessed by the Oral Assessment Guide). Aim: To demonstrate that improvement in patient satisfaction and quality of life scores outweighs the potential risks of aspiration of plain water in an acute care setting; to qualitatively assess the implementation of a Free Water Protocol from the viewpoints of the patient and family/caregivers; to quantify changes in oral hygiene practices for individuals on the Free Water Protocol.

NCT ID: NCT06309355 Not yet recruiting - Atopic Dermatitis Clinical Trials

Topical YR001 Ointment in Adult With Mild to Moderate Atopic Dermatitis

Start date: June 2024
Phase: Phase 2
Study type: Interventional

This study is to evaluate the safety, tolerability, and pharmacokinetics of YR001 topical ointment in adult patients with mild to moderate atopic dermatitis

NCT ID: NCT06309134 Not yet recruiting - Alcohol Drinking Clinical Trials

The Healthy Families Bright Futures Program

Start date: October 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to learn about an online group program (Healthy Families Bright Futures program) for LGBTQ+ teens and their caregivers. The main question[s] it aims to answer are: • is this program acceptable, appropriate, and feasible for LGBTQ+ youth and their caregivers • does the program affect teen (alcohol use, dating violence, alcohol use refusal self-efficacy, healthy communication self-efficacy) and caregiver (accepting behaviors, parenting self-efficacy, parenting behaviors) outcomes associated with risk for dating violence and alcohol use among LGBTQ+ teens. Participants will participate in a one-hour weekly online group for seven weeks with separate groups for teens and caregivers.

NCT ID: NCT06309017 Not yet recruiting - Clinical trials for Inflammatory Bowel Diseases

Pre-operative Nutrition for Elective Resection Surgery in Inflammatory Bowel Disease

Start date: March 10, 2024
Phase: N/A
Study type: Interventional

This study aims to determine if improved risk stratification tools and interventions to mitigate malnutrition reduce postoperative risk in patients undergoing elective or emergent resection surgery for inflammatory bowel disease (IBD), and if adding immune modulation nutrition improves surgical outcomes. The primary objective is to assess whether preoperative malnutrition screening and intervention minimize postoperative complications. The secondary objective is to evaluate whether immune modulation nutrition in the peri-operative period decreases length of stay and major complications.

NCT ID: NCT06308718 Not yet recruiting - Krabbe Disease Clinical Trials

Long-term Follow-up Study to Evaluate Safety and Efficacy of FBX-101 in Krabbe Patients

Start date: June 2024
Phase:
Study type: Observational

This is an observational study that will enroll any patients with Krabbe disease that have participated in prior interventional clinical trials involving the administration of FBX-101.

NCT ID: NCT06308588 Not yet recruiting - Clinical trials for Acute Lymphoblastic Leukemia

Phase II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Start date: September 30, 2024
Phase: Phase 2
Study type: Interventional

To learn if the combination of blinatumomab and asciminib can help to control Ph+ ALL.

NCT ID: NCT06308575 Not yet recruiting - Clinical trials for Metastatic Olfactory Neuroblastoma

A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma

Start date: September 30, 2024
Phase: Phase 2
Study type: Interventional

To learn if rivoceranib can help to control olfactory neuroblastoma. The safety of this drug in participants with olfactory neuroblastoma will also be studied.